Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03241784 · ClinicalTrials.gov registry record · Phase 1
Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03241784: Completed Phase 1 study, sponsored by The Methodist Hospital Research Institute.
NCT03241784 is a Phase 1 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03241784, a Phase 1 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS.
Primary Outcome
Adverse events and serious adverse events related to Treg infusions were monitored throughout the study.
Interventions
- BIOLOGICAL Interleukin-2
- BIOLOGICAL Autologous T-regulatory lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-05-16 |
| Est. Completion | 2018-04-10 |
| Phase | Phase 1 |
What the finished NCT03241784 record still lists
NCT03241784 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Interleukin-2 is the first listed.
NCT03241784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03241784 about?
NCT03241784 is a clinical study titled "Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis". Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS.
What is the current status of trial NCT03241784?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2016-05-16. Estimated completion is 2018-04-10.
What interventions are being tested in trial NCT03241784?
The interventions under investigation include: Interleukin-2 (BIOLOGICAL), Autologous T-regulatory lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT03241784?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03241784's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI